European Medical Solutions
ALEMS
Company Profile
Business description
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
Contact
7 Rue des Chasseurs Ardennais
Liege4031
BELT: +32 471563533
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
129
Stocks News & Analysis
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
stocks
3 global ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,120.90 | 34.10 | 0.38% |
| CAC 40 | 7,928.34 | 103.10 | 1.32% |
| DAX 40 | 23,828.88 | 130.73 | 0.55% |
| Dow JONES (US) | 45,834.22 | 273.78 | -0.59% |
| FTSE 100 | 9,283.37 | 0.08 | 0.00% |
| HKSE | 26,446.56 | 58.40 | 0.22% |
| NASDAQ | 22,141.10 | 98.03 | 0.44% |
| Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
| NZX 50 Index | 13,208.31 | 19.59 | -0.15% |
| S&P 500 | 6,584.29 | 3.18 | -0.05% |
| S&P/ASX 200 | 8,853.00 | 31.60 | 0.36% |
| SSE Composite Index | 3,860.50 | 10.09 | -0.26% |